Navigation Links
Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Date:7/31/2008

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present information on platinum resistance at the Fourth Annual Moores UCSD Cancer Center Translational Oncology Symposium on Friday, August 1, in San Diego.

Neela Patel, Ph.D., director of preclinical and translational medicine for Poniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms of Platinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairman and chief executive officer, will participate in the symposia's concluding panel discussion at 3:15 p.m. Pacific Time.

"Each year, 300,000 cancer patients in the United States are treated with a platinum-based chemotherapy, and most relapse after initial treatment," said Dr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is a significant treatment issue. Picoplatin, our lead product candidate, was designed to overcome platinum resistance, and we are exploring the use of genetic markers of platinum resistance to optimize patient treatment."

About The Rebecca and John Moores UCSD Cancer Center

The Rebecca and John Moores UCSD Cancer Center seeks to bring the finest minds in treatment and research under one roof to share the latest advances in the oncology field, and to create a fertile atmosphere that promotes networking and collaboration opportunities of benefit to all participants.

Information about the Moores UCSD Cancer Center and the Translational Oncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... is now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing ... saw clear demand for Microsoft Azure from major institutions collecting and analyzing genomic ...
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November ... Business Conference will bring together over 500 top healthcare leaders for a night and ... The conference, organized by MBA students of the University of Pennsylvania’s Wharton School, will ...
(Date:2/9/2016)... ... February 09, 2016 , ... Clinovo , the ... validated Electronic Data Capture (EDC) system ClinCaptureand its new Contract Research Organization (CRO) ... 2016 Conference in San Mateo, California on February 10th and 11th. Watch ...
(Date:2/9/2016)... ... 2016 , ... PharmApprove announced today the hiring ... for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work with patients, ... drug regulatory review process. , “Adding Diane Dorman is just the latest in ...
Breaking Biology Technology:
(Date:1/13/2016)... --> --> ... report titled - Biometric Sensors Market - Global Industry Analysis, ... to the report, the global biometric sensors market was valued at ... US$1,625.8 mn by 2023, expanding at a CAGR of ... the biometric sensors market is expected to reach 1,799.6 ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
(Date:1/7/2016)... NEW YORK , Jan. 7, 2016 ... as regional markets for biometric technologies and devices, identifying ... application market for various types of biometric devices. Includes ... report to: Identify newer markets and explore the ... of biometric devices. Examine each type of biometric technology, ...
Breaking Biology News(10 mins):